Denali Therapeutics Inc.

US$20.07As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:DNLIHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR 2.86%
Div yield —
ROE (33.94%)
Biotechnology
Beta (5Y) 1.08
PE TTM —
TSR TTM 23.28%
Mkt cap US$3.217B
ROIC (174.56%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$22
7.28%
(22.07%)
Hold 8|8|8|0|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.22
0.23
0.26
0.29
2.61%
6.20%
17.57%
32.37%
Revenue$M
263.4
257.0
250.1
254.3
0.16%
(5.32%)
(5.39%)
(4.84%)
Peers (US$3.217B)
Cap (US$)
PE
3.268B
—
Capital
TTM
5Y
10Y
Leveragex
1.285
0.062
0.064
EBIT/Intx
2.499
1.371
0.822
Own earn%
(544.60)
3.50
0.90
Sh yield%
49.63
48.41
48.26
Owners
Insiders/Inst%
3.82
77.50
Short interest%
5.11
SBC / revenue%
4.97
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
22–31
$1 testx
—
Incr. ROIC%
11